403 related articles for article (PubMed ID: 21456105)
1. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
2. A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.
Nandi A; Pal P; Basu S
Rheumatol Int; 2019 Oct; 39(10):1797-1801. PubMed ID: 31302740
[TBL] [Abstract][Full Text] [Related]
3. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
4. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Nakagama Y; Inuzuka R; Hayashi T; Shindo T; Hirata Y; Shimizu N; Inatomi J; Yokoyama Y; Namai Y; Oda Y; Takamizawa M; Harita Y; Oka A
Pediatr Int; 2016 Mar; 58(3):180-184. PubMed ID: 26222760
[TBL] [Abstract][Full Text] [Related]
5. N-terminal pro-brain natriuretic peptide (NT proBNP) as a predictive indicator of initial intravenous immunoglobulin treatment failure in children with Kawasaki disease: a retrospective study.
Kim SY; Han MY; Cha SH; Jeon YB
Pediatr Cardiol; 2013; 34(8):1837-43. PubMed ID: 23744100
[TBL] [Abstract][Full Text] [Related]
6. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T; Wang Y; Fu S; Wang W; Xie C; Zhang Y; Gong F
Pediatr Rheumatol Online J; 2017 Mar; 15(1):17. PubMed ID: 28320400
[TBL] [Abstract][Full Text] [Related]
7. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
Wang JR; Zhao HZ; Chang LJ; Xu X; Gao Y; Li M; Kong QY; Wang MM; Zhao CF
Eur J Pediatr; 2023 Oct; 182(10):4399-4406. PubMed ID: 37480545
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of albumin for intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients.
Zhang R; Shuai S; Zhang H; Cai J; Cui N; Tang M; Xing S; Gao Y; Liu X; Yang X
Ital J Pediatr; 2023 Jun; 49(1):78. PubMed ID: 37357258
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[TBL] [Abstract][Full Text] [Related]
12. Inability of Asian risk scoring systems to predict intravenous immunoglobulin resistance and coronary lesions in Kawasaki disease in an Italian cohort.
Fabi M; Andreozzi L; Corinaldesi E; Bodnar T; Lami F; Cicero C; Tchana B; Landini C; Sprocati M; Bigucci B; Balsamo C; Sogno Valin P; Di Fazzio G; Iughetti L; Valletta E; Marchetti F; Donti A; Lanari M
Eur J Pediatr; 2019 Mar; 178(3):315-322. PubMed ID: 30499051
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
Wu Y; Liu FF; Xu Y; Wang JJ; Samadli S; Wu YF; Liu HH; Chen WX; Luo HH; Zhang DD; Wei W; Hu P
Clin Exp Med; 2019 May; 19(2):173-181. PubMed ID: 30617865
[TBL] [Abstract][Full Text] [Related]
14. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
[TBL] [Abstract][Full Text] [Related]
15. Ulinastatin therapy in kawasaki disease.
Iwashima S; Seguchi M; Matubayashi T; Ohzeki T
Clin Drug Investig; 2007; 27(10):691-6. PubMed ID: 17803344
[TBL] [Abstract][Full Text] [Related]
16. Indicators of unresponsiveness after initial i.v. immunoglobulin treatment in acute Kawasaki disease.
Hashimoto I
Pediatr Int; 2019 Jul; 61(7):641-646. PubMed ID: 31132210
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ; Jung JW
Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
[TBL] [Abstract][Full Text] [Related]
18. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Liang CD; Wang CL; Yu HR; Hwang KP; Yang KD
Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
[TBL] [Abstract][Full Text] [Related]
19. The role of serum lipid in predicting coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease: a cohort study.
Zhang H; Cai J; Zhang R; Shuai S; Tang M; Ju R; Hu Y; Zuo T; Yang Y
J Int Med Res; 2024 May; 52(5):3000605241252115. PubMed ID: 38713460
[TBL] [Abstract][Full Text] [Related]
20. Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease.
Huang XB; Zhao S; Liu ZY; Xu YY; Deng F
Ann Med; 2023; 55(2):2264315. PubMed ID: 37870383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
